Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
83.67
-3.49 (-4.00%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Dianthus Therapeutics Employees
Dianthus Therapeutics had 92 employees as of December 31, 2025. The number of employees increased by 14 or 17.95% compared to the previous year.
Employees
92
Change (1Y)
14
Growth (1Y)
17.95%
Revenue / Employee
$22,130
Profits / Employee
-$1,764,533
Market Cap
4.56B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 92 | 14 | 17.95% |
| Dec 31, 2024 | 78 | 25 | 47.17% |
| Dec 31, 2023 | 53 | 21 | 65.63% |
| Dec 31, 2022 | 32 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Caris Life Sciences | 1,846 |
| Apellis Pharmaceuticals | 739 |
| Corcept Therapeutics | 730 |
| Crinetics Pharmaceuticals | 594 |
| Amicus Therapeutics | 511 |
| TG Therapeutics | 399 |
| CRISPR Therapeutics AG | 393 |
DNTH News
- 22 days ago - Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 7 weeks ago - Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering - GlobeNewsWire
- 7 weeks ago - Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering - GlobeNewsWire
- 7 weeks ago - Dianthus Therapeutics Stock Rallies—Rare Disease Study Success Fuels Optimism - Benzinga
- 7 weeks ago - Dianthus Therapeutics Transcript: Study result - Transcripts
- 7 weeks ago - Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results - GlobeNewsWire
- 7 weeks ago - Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - GlobeNewsWire